Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Konkordia West | Pharma | 41.6% | 93rd pct | 110 |
| Kordeksi | Pharma | 35.8% | 85th pct | 110 |
| Portres Parmasiutikal T… | Pharma | 7.7% | 34th pct | 110 |
| Velpar Geo | Pharma | 6.5% | 27th pct | 110 |
| Modern Medical Solutions | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2022 (5 of 5).
| Ratio — FY 2024 | Portres Parmasiutikal T… | Velpar Geo | Kordeksi | Konkordia West | Modern Medical Solutions |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 9.0% | 31.2% | 66.5% | 51.7% | — |
| EBITDA Margin | 7.7% | 6.5% | 35.8% | 41.6% | — |
| EBITDAR | 866 | 791 | 3,628 | 4,231 | — |
| EBITDAR Margin | 8.2% | 7.7% | 35.8% | 41.8% | — |
| EBIT Margin | 7.7% | 6.1% | 35.0% | 41.6% | — |
| Net Profit Margin | 3.6% | -2.6% | 34.7% | 40.9% | — |
| Operating Expense % of Sales | 1.2% | 24.6% | 30.7% | 10.2% | — |
| Returns | |||||
| Return on Assets (ROA) | 4.2% | -3.2% | 35.6% | 23.2% | — |
| Return on Equity (ROE) | N/A | -6.0% | 41.6% | 23.6% | — |
| ROIC [EBIT / Invested Capital] | N/A | ||||
| 13.9% |
| 48.5% |
| 24.3% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.5% | 3.7% | 0.0% | — |
| Debt-to-Equity | -0.00x | 0.01x | 0.04x | 0.00x | — |
| Debt-to-EBITDA | 0.00x | 0.07x | 0.10x | 0.00x | — |
| Equity-to-Assets | -64.0% | 54.5% | 85.6% | 98.3% | — |
| Net Debt | -384 | -32 | -1,137 | -192 | — |
| Cash & Equivalents | 384 | 78 | 1,501 | 192 | — |
| Total Debt | N/A | 45 | 364 | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.61x | 2.18x | 7.99x | 24.50x | — |
| Quick Ratio | 0.61x | 2.18x | 7.99x | 24.50x | — |
| Cash Ratio | 0.03x | 0.02x | 1.41x | 0.62x | — |
| Total Current Assets | 8,937 | 8,095 | 8,504 | 7,583 | — |
| Total Current Liabilities | 14,763 | 3,709 | 1,064 | 309 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 6,673 | 4,773 | 5,596 | 7,390 | — |
| Trade Payables | 14,924 | 3,696 | 965 | 109 | — |
| Net Working Capital | -5,826 | 4,386 | 7,439 | 7,273 | — |
| Net Working Capital % of Revenue | -55.2% | 42.8% | 73.4% | 71.8% | — |
| Trade Working Capital | -8,251 | 1,077 | 4,631 | 7,282 | — |
| Trade Working Capital % of Revenue | -78.2% | 10.5% | 45.7% | 71.9% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 1.58x | 2.15x | 1.81x | 1.37x | — |
| Days Sales Outstanding (DSO) | 230.8 | 169.8 | 201.5 | 266.2 | — |
| Payables Turnover | 0.64x | 1.91x | 3.52x | 45.04x | — |
| Days Payable Outstanding (DPO) | 567.1 | 191.0 | 103.7 | 8.1 | — |
| Cash Conversion Cycle | -336.3 days | -21.2 days | 97.8 days | 258.1 days | — |
| Asset Turnover | 1.16x | 1.24x | 1.03x | 0.57x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | -214 | 569 | N/A | -223 | — |
| Free Cash Flow (OCF − Capex proxy) | -214 | -93 | N/A | -223 | — |
| Cash Conversion (OCF / EBITDA) | -26.2% | 85.1% | N/A | -5.3% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |